Researchers at the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust have developed a new treatment that can eliminate tumors in terminally ill patients with head and neck cancer. The study was conducted with a cocktail of immunotherapy drugs, which used the patients’ immune systems to kill their own cancer cells.
Scientists found that the combination of two drugs called nivolumab and ipilimumab led to a reduction in tumor size in terminally ill patients with head and neck cancer. In some, the cancer has completely disappeared. As a result, experts believe that the combination of these immunotherapy drugs could prove to be an effective new weapon against various forms of advanced cancer.
In addition to increasing these patients’ long-term survival chances, immunotherapy treatment also triggered fewer side effects. The study involved nearly 1,000 patients with head and neck cancer. “Immunotherapies are gentler and more intelligent treatments [que as químio ou radioterapias] and can bring significant benefits to patients,” say the researchers.
Want to catch up on the best tech news of the day? Access and subscribe to our new youtube channel, Canaltech News. Everyday a summary of the main news from the tech world for you!
The study results show that the combination immunotherapy had a particularly high success rate in a group of patients whose tumors had high levels of an immunological marker called PD-L1. Survival rates in those with high levels of PD-L1 who received the immunotherapy cocktail were the highest ever reported in such a trial. The researchers hope the findings will show more benefits from the therapy in patients with advanced head and neck cancers.
Source: The Guardian
Did you like this article?
Subscribe your email on Canaltech to receive daily updates with the latest news from the world of technology.